Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

81. Systematic review with meta-analysis: Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection

Systematic review with meta-analysis: Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection Article Text Aetiology Systematic review

2013 Evidence-Based Medicine (Requires free registration)

82. Cohort study: The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices

Cohort study: The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The association between proton pump inhibitor use and hip fracture cannot be explained by differences

2013 Evidence-Based Medicine (Requires free registration)

83. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists (Full text)

Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists Barkun AN, Adam V, Martel M, Bardou M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of two types of drug to prevent stress ulcer bleeding in patients in the intensive care unit. The authors concluded that a proton pump inhibitor was more efficient than a histamine 2-receptor antagonist in preventing bleeding from a stress ulcer

2013 NHS Economic Evaluation Database. PubMed

84. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome ? a systematic review

Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome ? a systematic review Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome – a systematic review Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome – a systematic review Jaspers Focks J, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW CRD summary This review concluded (...) that the evidence for the clinical consequences of clopidogrel given with proton-pump inhibitors was controversial. Prospective clinical studies did not support any adverse effects. These conclusions reflect the evidence and seem reliable; the limitations of the evidence should be borne in mind. Authors' objectives To evaluate the impact of clopidogrel plus proton-pump inhibitors on platelet function and cardiovascular outcomes for patients with acute coronary syndrome or stents for stable coronary disease

2013 DARE.

85. Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin

Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Article Text Aetiology Cohort study Lack

2013 Evidence-Based Medicine (Requires free registration)

86. Are Proton-Pump Inhibitors Effective Treatment for Acute Undifferentiated Upper Gastrointestinal Bleeding?

Are Proton-Pump Inhibitors Effective Treatment for Acute Undifferentiated Upper Gastrointestinal Bleeding? Systematic Review Snapshot TAKE-HOME MESSAGE In patients with acute upper gastrointestinal bleeding, proton-pump inhibitor treatment before indexendoscopydoesnotimprovepatient-importantoutcomes. Are Proton-Pump Inhibitors Effective Treatment for Acute Undifferentiated Upper Gastrointestinal Bleeding? EBEM Commentators Jennifer C. Cabot, MD Kaushal Shah, MD Department of Emergency Medicine (...) Mount Sinai Hospital New York, NY Results Six trials with a total of 2,223 partici- pants were included. All studies were randomized controlled trials with a parallel-group design, conducted in a hospital setting. Four trials were con- ducted in Europe and 2 in Asia. There was no signi?cant heterogeneity among the trials (Table 2). Compared with the control group, proton-pump inhibitor treatment did not affect the rates of 30-day mortality, rebleeding, surgery, or blood transfusion (Table 1

2013 Annals of Emergency Medicine Systematic Review Snapshots

87. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review (PubMed)

Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review Clopidogrel as an adjunct to aspirin has improved outcomes after acute coronary syndromes, but laboratory studies suggest a reduced antiplatelet effect when proton pump inhibitors (PPIs) are co-administered. Despite corroborating data from retrospective studies, new clinical data fuel the controversy on this issue.Systematic review of the impact of the addition

2013 EvidenceUpdates

88. Esophageal reflux disease proton pump inhibitor therapy impact on sleep disturbance: a systematic review

Esophageal reflux disease proton pump inhibitor therapy impact on sleep disturbance: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

89. [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan]

[Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan] Portrait de l'usage des inhibiteurs de la pompe à protons (IPP) chez les adultes assurés par le régime public d'assurance médicaments [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan] Portrait de l'usage des inhibiteurs de la pompe à protons (IPP) chez les adultes assurés par le régime public (...) d'assurance médicaments [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan] L'Institut national d'excellence en sante et en services sociaux (INESSS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation L'Institut national d'excellence en sante et en services sociaux (INESSS

2012 Health Technology Assessment (HTA) Database.

90. Review: Proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. (PubMed)

Review: Proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. 22910967 2012 10 19 2012 08 22 1539-3704 157 4 2012 Aug 21 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: review: proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. JC2-13 10.7326/0003-4819-157-4-201208210-02013 Koretz Ronald L RL Olive View-UCLA Medical Center Sylmar, California, USA. eng Comment Journal Article United States Ann

2012 Annals of Internal Medicine

91. Proton Pump Inhibitors vs. Histamine 2 Receptor Antagonists for Stress-Related Mucosal Bleeding Prophylaxis in Critically Ill Patients: A Meta-Analysis (PubMed)

Proton Pump Inhibitors vs. Histamine 2 Receptor Antagonists for Stress-Related Mucosal Bleeding Prophylaxis in Critically Ill Patients: A Meta-Analysis H2-receptor antagonists (H2RA) have been shown to reduce stress-related mucosal bleeding (SRMB), yet randomized controlled trials assessing proton pump inhibitors (PPIs) have yielded conflicting results. The objective of this study was to evaluate the efficacy of PPIs vs. H2RAs in the prophylaxis of SRMB in critically ill adults with risk

2012 EvidenceUpdates

92. Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial (Full text)

Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial The clinical significance of the interaction between clopidogrel and proton pump inhibitors (PPIs) remains unclear.We examined the relationship between PPI use and 1-year cardiovascular events (cardiovascular death, myocardial infarction, or stroke) in patients with acute coronary syndrome randomized to clopidogrel or ticagrelor

2012 EvidenceUpdates PubMed

93. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis

Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

94. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. (Full text)

Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. To examine the association between chronic use of proton pump inhibitors (PPIs) and risk of hip fracture.Prospective cohort study.Nurses' Health Study, which originally recruited from the 11 most populous states in the US.79,899 postmenopausal women enrolled in the Nurses' Health Study who provided data on the use of PPIs and other risk factors biennially since 2000

2012 BMJ PubMed

95. Proton pump inhibitors in long-term use: reports of hypomagnesaemia

Proton pump inhibitors in long-term use: reports of hypomagnesaemia Proton pump inhibitors in long-term use: reports of hypomagnesaemia - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Proton pump inhibitors in long-term use: reports of hypomagnesaemia Healthcare professionals should consider measuring magnesium levels before starting PPI treatment and repeat measurements periodically during prolonged treatment. Published 11 December 2014 From: Therapeutic area: Contents Article (...) date: April 2012 Proton pump inhibitors (PPIs) are a class of drugs for the treatment of duodenal and gastric ulcers, and are used in combination with antibacterials for the eradication of Helicobacter pylori. They are also used to treat gastroesophageal reflux disease, dyspepsia, and Zolligner-Ellison syndrome and for prevention and treatment of ulcers associated with the use of non-steroidal anti-inflammatory drugs. The class of PPIs includes esomeprazole (Nexium), lansoprazole (Zoton

2012 MHRA Drug Safety Update

96. Proton pump inhibitors in long-term use: increased risk of fracture

Proton pump inhibitors in long-term use: increased risk of fracture Proton pump inhibitors in long-term use: increased risk of fracture - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Proton pump inhibitors in long-term use: increased risk of fracture Recent epidemiological evidence of an increased risk of fracture with long-term use of proton pump inhibitors (PPIs). Published 11 December 2014 From: Therapeutic area: Contents Article date: April 2012 Observational studies

2012 MHRA Drug Safety Update

97. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease (PubMed)

Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease Unexplained chest pain is potentially attributable to gastro-oesophageal reflux disease (GORD) or oesophageal motility disorders. Reflux chest pain may occur without heartburn. We explored the response of unexplained chest pain to proton pump inhibitor (PPI) therapy in randomised clinical trials (RCTs), differentiating patients

2012 EvidenceUpdates

98. Cohort study: Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events

Cohort study: Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events Article Text Prognosis Cohort study Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events David N Juurlink Statistics from Altmetric.com Commentary on: Charlot M , Grove EL , Hansen PR , et al . Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time

2012 Evidence-Based Medicine (Requires free registration)

99. Randomised controlled trial: Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors

Randomised controlled trial: Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you (...) Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors Article Text Therapeutics Randomised controlled trial Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors George Triadafilopoulos Statistics from Altmetric.com Commentary on: Galmiche JP , Hatlebakk J , Attwood

2012 Evidence-Based Medicine (Requires free registration)

100. Celecoxib versus Non-COX-2 Selective Non-steroidal Anti-inflammatory Drugs and Proton Pump Inhibitors: A Review of the Clinical Effectiveness, Safety, and Cost Effectiveness

Celecoxib versus Non-COX-2 Selective Non-steroidal Anti-inflammatory Drugs and Proton Pump Inhibitors: A Review of the Clinical Effectiveness, Safety, and Cost Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence (...) be copied and used for non-commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Celecoxib versus Non-selective Non-steroidal Anti-Inflammatory Drugs and Proton Pump Inhibitors: Clinical Effectiveness, Safety, and Cost-Effectiveness

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review